Euphoria was investors' reaction to news that Hansen Medical (NASDAQ:HNSN) was granted clearance for its Robotic Catheter eKit from US authorities and the company's shares advanced 50%.
Although widely touted as ripe for clearance, the news that Hansen Medical's Magellan Robotic Catheter eKit had received the nod from the US Food and Drug Administration came as some relief.
Shares raced up by as much as 50.6% to US$4.82 earlier, having traded at around US$2 in the last week of January. The price was last seen up 29%, or 92 cents at USD4.12.
The eKits allow doctors to control third party microcatheters robotically through current Megellan Robotic Catheter 6Fr architecture. The goal of the kits is to help reduce exposure time to radiation and overall procedure time.